Quarterly report pursuant to Section 13 or 15(d)

Commitment and Contingencies - Additional Information (Details)

v3.22.2
Commitment and Contingencies - Additional Information (Details)
3 Months Ended 6 Months Ended
Sep. 08, 2020
Debtinstrument
Jan. 21, 2020
Debtinstrument
Jun. 30, 2022
UsdRln
Jun. 30, 2022
USD ($)
UsdRln
Nov. 18, 2015
USD ($)
Royalty-Linked Notes          
Other Commitments [Line Items]          
Debt instrument outstanding portion | UsdRln       0.04  
Debt instrument maturity date       Dec. 31, 2045  
Debt instrument, aggregate potential payment capped rate       4,000  
Pfizer License Agreement | Royalty-Linked Notes          
Other Commitments [Line Items]          
Debt instrument outstanding portion | UsdRln     0.04    
Debt instrument maturity date       Dec. 31, 2045  
Debt instrument price per unit       $ 160.00  
Debt instrument, aggregate potential payment capped rate       4,000  
Pfizer License Agreement | Royalty-Linked Notes | Private Placement          
Other Commitments [Line Items]          
Number of debt instruments within each notes | Debtinstrument   2,579,400      
Pfizer License Agreement | Royalty-Linked Notes | Rights Offering          
Other Commitments [Line Items]          
Number of debt instruments within each notes | Debtinstrument 11,000        
Pfizer License Agreement | Minimum          
Other Commitments [Line Items]          
Potential future regulatory milestone and sales milestone payments upon achievement of net sales         $ 250,000,000.0
Pfizer License Agreement | Maximum          
Other Commitments [Line Items]          
Potential future regulatory milestone and sales milestone payments upon achievement of net sales         $ 1,000,000,000.0